312 related articles for article (PubMed ID: 26071982)
21. Use of catechol-O-methyltransferase inhibition to minimize L-3,4-dihydroxyphenylalanine-induced dyskinesia in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque.
Huot P; Johnston TH; Snoeren T; Koprich JB; Hill MP; Fox SH; Brotchie JM
Eur J Neurosci; 2013 Mar; 37(5):831-8. PubMed ID: 23281915
[TBL] [Abstract][Full Text] [Related]
22. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
Rose S; Jackson MJ; Smith LA; Stockwell K; Johnson L; Carminati P; Jenner P
Eur J Pharmacol; 2006 Sep; 546(1-3):82-7. PubMed ID: 16925991
[TBL] [Abstract][Full Text] [Related]
23. Trazodone alleviates both dyskinesia and psychosis in the parkinsonian marmoset model of Parkinson's disease.
Hamadjida A; Nuara SG; Gourdon JC; Huot P
J Neural Transm (Vienna); 2018 Sep; 125(9):1355-1360. PubMed ID: 29247391
[TBL] [Abstract][Full Text] [Related]
24. A preclinical study on the combined effects of repeated eltoprazine and preladenant treatment for alleviating L-DOPA-induced dyskinesia in Parkinson's disease.
Ko WKD; Li Q; Cheng LY; Morelli M; Carta M; Bezard E
Eur J Pharmacol; 2017 Oct; 813():10-16. PubMed ID: 28739086
[TBL] [Abstract][Full Text] [Related]
25. The selective mu-opioid receptor antagonist ADL5510 reduces levodopa-induced dyskinesia without affecting antiparkinsonian action in MPTP-lesioned macaque model of Parkinson's disease.
Koprich JB; Fox SH; Johnston TH; Goodman A; Le Bourdonnec B; Dolle RE; DeHaven RN; DeHaven-Hudkins DL; Little PJ; Brotchie JM
Mov Disord; 2011 Jun; 26(7):1225-33. PubMed ID: 21465551
[TBL] [Abstract][Full Text] [Related]
26. UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances L-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset.
Huot P; Johnston TH; Lewis KD; Koprich JB; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
Neuropharmacology; 2014 Jul; 82():76-87. PubMed ID: 24447715
[TBL] [Abstract][Full Text] [Related]
27. Characterization of 3,4-methylenedioxymethamphetamine (MDMA) enantiomers in vitro and in the MPTP-lesioned primate: R-MDMA reduces severity of dyskinesia, whereas S-MDMA extends duration of ON-time.
Huot P; Johnston TH; Lewis KD; Koprich JB; Reyes MG; Fox SH; Piggott MJ; Brotchie JM
J Neurosci; 2011 May; 31(19):7190-8. PubMed ID: 21562283
[TBL] [Abstract][Full Text] [Related]
28. 5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA.
Huot P; Johnston TH; Winkelmolen L; Fox SH; Brotchie JM
Neurobiol Aging; 2012 Jan; 33(1):194.e5-15. PubMed ID: 20561716
[TBL] [Abstract][Full Text] [Related]
29. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.
Hansard MJ; Smith LA; Jackson MJ; Cheetham SC; Jenner P
Mov Disord; 2004 Jan; 19(1):15-21. PubMed ID: 14743355
[TBL] [Abstract][Full Text] [Related]
30. An evaluation of istradefylline treatment on Parkinsonian motor and cognitive deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque models.
Ko WKD; Camus SM; Li Q; Yang J; McGuire S; Pioli EY; Bezard E
Neuropharmacology; 2016 Nov; 110(Pt A):48-58. PubMed ID: 27424102
[TBL] [Abstract][Full Text] [Related]
31. Neuroinflammation and L-dopa-induced abnormal involuntary movements in 6-hydroxydopamine-lesioned rat model of Parkinson's disease are counteracted by combined administration of a 5-HT
Pinna A; Costa G; Serra M; Contu L; Morelli M
Neuropharmacology; 2021 Sep; 196():108693. PubMed ID: 34229013
[TBL] [Abstract][Full Text] [Related]
32. Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset.
Sid-Otmane L; Hamadjida A; Nuara SG; Bédard D; Gaudette F; Gourdon JC; Michaud V; Beaudry F; Panisset M; Huot P
Eur J Pharmacol; 2020 Apr; 873():172957. PubMed ID: 32004527
[TBL] [Abstract][Full Text] [Related]
33. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
Grégoire L; Samadi P; Graham J; Bédard PJ; Bartoszyk GD; Di Paolo T
Parkinsonism Relat Disord; 2009 Jul; 15(6):445-52. PubMed ID: 19196540
[TBL] [Abstract][Full Text] [Related]
34. Effect of serotonin transporter blockade on L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
Fidalgo C; Ko WK; Tronci E; Li Q; Stancampiano R; Chuan Q; Bezard E; Carta M
Neuroscience; 2015 Jul; 298():389-96. PubMed ID: 25907446
[TBL] [Abstract][Full Text] [Related]
35. Continuous administration of rotigotine to MPTP-treated common marmosets enhances anti-parkinsonian activity and reduces dyskinesia induction.
Stockwell KA; Scheller D; Rose S; Jackson MJ; Tayarani-Binazir K; Iravani MM; Smith LA; Olanow CW; Jenner P
Exp Neurol; 2009 Oct; 219(2):533-42. PubMed ID: 19619533
[TBL] [Abstract][Full Text] [Related]
36. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of L-DOPA and dopamine agonists in MPTP-treated common marmosets.
Uchida S; Soshiroda K; Okita E; Kawai-Uchida M; Mori A; Jenner P; Kanda T
Eur J Pharmacol; 2015 Nov; 766():25-30. PubMed ID: 26415982
[TBL] [Abstract][Full Text] [Related]
37. Effect of the glycine transporter 1 inhibitor ALX-5407 on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset.
Frouni I; Belliveau S; Maddaford S; Nuara SG; Gourdon JC; Huot P
Eur J Pharmacol; 2021 Nov; 910():174452. PubMed ID: 34480885
[TBL] [Abstract][Full Text] [Related]
38. A Selective Phosphodiesterase 10A Inhibitor Reduces L-Dopa-Induced Dyskinesias in Parkinsonian Monkeys.
Beck G; Maehara S; Chang PL; Papa SM
Mov Disord; 2018 May; 33(5):805-814. PubMed ID: 29508924
[TBL] [Abstract][Full Text] [Related]
39. Synergistic antidyskinetic effects of topiramate and amantadine in animal models of Parkinson's disease.
Kobylecki C; Hill MP; Crossman AR; Ravenscroft P
Mov Disord; 2011 Nov; 26(13):2354-63. PubMed ID: 21953539
[TBL] [Abstract][Full Text] [Related]
40. Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset.
Hamadjida A; Nuara SG; Kwan C; Frouni I; Bédard D; Gourdon JC; Huot P
Naunyn Schmiedebergs Arch Pharmacol; 2020 Nov; 393(11):2157-2164. PubMed ID: 32621059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
